LAS VEGAS and BUENOS AIRES, Argentina, Sept. 27, 2011 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, today updated shareholders on the progress of Biocordcell Argentina S.A. (BioCells, Inc.), which is 50.1 percent owned by Cord Blood America.
"January through August revenues in 2011 are up 40 percent to $1.18 million (U.S.)," said Diego Rissola, president of BioCells, Inc. "The increase in revenues reflects the fact that we have established franchises in six provinces in Argentina and we opened an office in Miami, Florida, to service the Latin American population there. We are now signing 11 percent more new contracts than we did in the same period in 2010."
"We have been successful with e-marketing, using a new web page and social media. We also now have operations in Brazil and the Dominican Republic, and the development of storing dental pulp is proving to be a potential revenue enhancer for the Company," Mr. Rissola said.
"BioCells of Argentina has performed fantastically in a down global economy. We've realized great growth, profitability, just a good story all around. We're fortunate to have purchased the control position of this ever expanding company," said Matthew Schissler, CEO of Cord Blood America.
(Revenue and other financial estimates contained in this press release have not been audited or reviewed by Cord Blood America's independent auditors. The Company provides no assurance that these preliminary results will not change following the completion of its financial audit for Fiscal 2011.)
About Cord Blood America
Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.
CONTACT:
Paul Knopick
E & E Communications
949/707-5365
pknopick@eandecommunications.com
SOURCE Cord Blood America, Inc.
